The U.S. market for biochip products and services is stimulated by the rising adoption of proteomics and genomics in cancer treatment research, which results in the utilization of reagents and microarrays. In addition, as per the report, the rise in life science research, personalized medicine, and drug discovery, coupled with advancements such as the approval from the U.S. FDA for personalized medicines in treating lung cancer and melanoma, is predicted to fuel the market in the Forecast period. Advancement of nanotechnology increases the capability and reduces the size of biochips and makes them useful for diagnostics, research, drug development, and toxicology studies which have led to growing adoption of biochips in various applications. These chips are now widely used in genomics, proteomics, personalized medicine, and other applications which prompt existing manufacturers and new startups to develop, invest, and introduce new technology in the market.

Market Dynamics

The key market players are focusing on the adoption of growth and organic strategies such as the launch of new biochips, which is attributed to the growth of the U.S. Biochip Product & Services market. For instance, on April 13, 2023, Agilent Technologies Inc. delivers complete scientific solutions, announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers. The assay workflow is efficient, automatable, and flexible, making tumor molecular profiling more accessible to the broad clinical research community.

 Key features of the study:

• This report provides an in-depth analysis of the S. Biochip Product & Services market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. Biochip Product & Services market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Affymetrix Inc., Beckman Coulter, Inc., Illumina Incorporated, Life Technologies Corporation, Randox Laboratories Ltd., Surfix B.V, GE Healthcare, Hoffmann-La Roche Ltd and AYOXXA Biosystems GmbH.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• S. Biochip Product & Services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. Biochip Product & Services market

Detailed Segmentation:

• U.S. Biochip Product & Services Market, By Type:
  • Products
    • Microarrays
    • Reagents & other Consumables
    • Others
  • Services
• U.S. Biochip Product & Services Market, By Application:
  • Drug Discovery
  • Life Science Research
  • IVD Tests 
  • Others
• Company Profiles
  • Abbott Laboratories 
  • Agilent Technologies
  • Affymetrix Inc.
  • Beckman Coulter, Inc.
  • Illumina Incorporated
  • Life Technologies Corporation
  • Randox Laboratories Ltd.
  • Surfix B.V
  • GE Healthcare
  • Hoffmann-La Roche Ltd
  • AYOXXA Biosystems GmbH.